KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 55 filers reported holding KALA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $17,000 | -26.1% | 75,420 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $23,000 | -77.9% | 75,420 | 0.0% | 0.00% | -75.0% |
| Q1 2022 | $104,000 | +50.7% | 75,420 | +30.8% | 0.00% | +33.3% |
| Q4 2021 | $69,000 | -54.3% | 57,670 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $151,000 | -50.7% | 57,670 | 0.0% | 0.01% | -57.1% |
| Q2 2021 | $306,000 | -21.3% | 57,670 | 0.0% | 0.01% | -30.0% |
| Q1 2021 | $389,000 | -0.5% | 57,670 | 0.0% | 0.02% | -9.1% |
| Q4 2020 | $391,000 | +8.3% | 57,670 | +20.1% | 0.02% | -4.3% |
| Q3 2020 | $361,000 | – | 48,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |